🇺🇸 FDA
Patent

US 11021468

TGF-ß inhibitors

granted A61PA61P35/02

Quick answer

US patent 11021468 (TGF-ß inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P35/02